Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sonnet BioTherapeutics Holdings, Inc. (SONN : NSDQ)

• Company Description    Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $5.28 Daily Weekly Monthly 20 Day Moving Average: 8,633,506 shares Shares Outstanding: 3.17 (millions) Market Capitalization: $16.72 (millions) Beta: 0.98 52 Week High: $8.72 52 Week Low: $1.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 347.46% 330.70% 12 Week 319.05% 252.48% Year To Date 261.64% 238.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 OVERLOOK CENTER SUITE 102 - PRINCETON,NJ 08540 USA ph: 609-375-2227 fax: 704-366-2463 sonn@jtcir.com http://www.sonnetbio.com

• General Corporate Information    Officers Pankaj Mohan - President; Chief Executive Officer and Chairman Jay Cross - Chief Financial Officer Albert Dyrness - Director Nailesh Bhatt - Director Raghu Rao - Director Peer Information Sonnet BioTherapeutics Holdings, Inc. (CORR.) Sonnet BioTherapeutics Holdings, Inc. (RSPI) Sonnet BioTherapeutics Holdings, Inc. (CGXP) Sonnet BioTherapeutics Holdings, Inc. (BGEN) Sonnet BioTherapeutics Holdings, Inc. (GTBP) Sonnet BioTherapeutics Holdings, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83548R402 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 3.17 Most Recent Split Date: 9.00 (0.13:1) Beta: 0.98 Market Capitalization: $16.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.46 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 24.45 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -258.93% vs. Previous Quarter: 42.95% Sales Growth vs. Year Ago Period: 5,163.16% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -777.92 12/31/24 - -408.93 ROA 06/30/25 - - 03/31/25 - -271.32 12/31/24 - -174.13 Current Ratio 06/30/25 - - 03/31/25 - 1.03 12/31/24 - 2.15 Quick Ratio 06/30/25 - - 03/31/25 - 1.03 12/31/24 - 2.15 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,312.60 12/31/24 - -927.00 Book Value 06/30/25 - - 03/31/25 - 0.22 12/31/24 - 1.32 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©